This post was originally published on this site A combination of the immunotherapies Keytruda (pembrolizumab) and CRS-207 is safe, but has no evidence of clinical activity in adults with malignant pleural mesothelioma who failed prior lines of therapy, a Phase 2 study shows. Based on the findings and on additional data from CRS-207’s program, the therapy’s clinical…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Molecular Patterns of Breast Cancer May Predict Chance of Relapse Up to 20 Years Later
This post was originally published on this site Screening a woman’s breast cancer for certain genetic and molecular patterns may be used to predict the risk of the cancer returning (relapsing) up to 20 years later, a study reports. Looking at the molecular data of breast tumors of nearly 2,000 women, researchers identified specific tumor…
Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma
This post was originally published on this site Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). The trials were approved by an independent ethics committee and will be conducted…
Collaboration to Explore How Gut Bacteria Might Bolster Immunotherapy
This post was originally published on this site Seres Therapeutics and AstraZeneca have established a research collaboration to unravel the mechanisms by which the microbiome – the natural, beneficial community of microbes living in the gut — might enhance the efficacy of cancer immunotherapies. “Our new collaboration with Seres Therapeutics represents an important opportunity to…
Robotic Prostatectomy is Popular, but Not Superior to Other Options, Study Says
This post was originally published on this site While current clinical data support no difference in the survival outcomes of prostate cancer patients after robotic surgery or radiation therapy, men tend to prefer surgery after consulting with their urologists and radiation oncologists, according to a small Australian study. Researchers found that treatment choices were primarily…
Uterine Fluid Analysis May Aid in Early Diagnosis of Aggressive OC
This post was originally published on this site Proteomic analysis — the characterization of all proteins present in a cell at a given time — in liquid biopsies from the womb may facilitate the early diagnosis of women who are genetically predisposed to develop high-grade ovarian cancer (HGOC), a study says. The study, “Microvesicle Proteomic…
Phase 1/2 Trial of Tinostamustine Recruiting Patients with Myeloma, Other Blood Cancers
This post was originally published on this site The expansion part of a Phase 1/2 clinical trial testing tinostamustine in relapsed or refractory blood cancers has begun treating the first patient. The trial (NCT02576496), conducted by Mundipharma EDO in collaboration with Imbrium Therapeutics, is currently seeking about 111 adult patients in the U.S. and Europe with either…
Majority of Sarcoidosis Patients Experience Fatigue, Survey Shows
This post was originally published on this site Fatigue is the most commonly reported symptom by sarcoidosis patients in Denmark, Germany, and the Netherlands, according to a survey conducted by researchers from those countries. Nerve damage-related symptoms are a close second. The study, “The Burden of Sarcoidosis Symptoms from a Patient Perspective” was published in…
Estrogen May Trigger Brain Metastasis in Triple-negative Breast Cancer, Study Shows
This post was originally published on this site Estradiol, a type of estrogen and the major female hormone, may drive the spread of cancer to the brain in women with triple-negative breast cancer (TNBC), a study in mice and human cells reports. Researchers identified a chain of molecular events triggered by estradiol that appears to…
Low White Blood Cell Count May Help Predict Some Ovarian Cancer Outcomes
This post was originally published on this site A reduced number of lymphocytes — one of the main types of immune cells — in advanced ovarian cancer patients before treatment is linked with a higher risk of disease worsening and shorter overall survival, according to a South Korean study. The study, “Pretreatment lymphocytopenia is an…
Darzalex Triple Combo Approved in England for Difficult-to-treat Multiple Myeloma
This post was originally published on this site A triple combination of Darzalex (daratumumab), Velcade (bortezomib), and dexamethasone will be available on the National Health Service (NHS) in England for the treatment of relapsed or refractory multiple myeloma patients. The U.K.’s National Institute of Health and Care Excellence (NICE) decided to approve the therapy based on…
Scotland Rejects NHS Access to Kymriah for Aggressive Diffuse Large B-cell Lymphoma
This post was originally published on this site Scotland’s healthcare system has rejected the use of Novartis‘ immunotherapy Kymriah (tisagenlecleucel) for adults with aggressive diffuse large B-cell lymphoma (DLBCL) who failed at least two prior lines of therapy. The Scottish Medicines Consortium (SMC) denied routine access to Kymriah through NHS Scotland based on “uncertainties in the company’s evidence around its…